Clinical Trial Update: Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update examining pegloticase for lowering uric acid in patients with tumor lysis syndrome; the study is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies
• Solid Tumors
• Tumor Lysis Syndrome

Drugs mentioned

• Pegloticase (pegloticase)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 4 | Status: ACTIVE_NOT_RECRUITING